NCT00705406已完成2 期
A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The Efficacy and Safety Of Intramuscular Peramivir 600 mg In Subjects With Uncomplicated Acute Influenza
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 405
- 试验地点
- 121
- 主要终点
- Time to Alleviation of Symptoms (Kaplan-Meier Estimate)
研究概览
简要总结
The purpose of this study is to determine whether peramivir is safe and effective in the treatment of uncomplicated seasonal influenza.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and non-pregnant female subjects age ≥18 years.
- •A positive Influenza A or B Rapid Antigen Test (RAT) performed with a commercially available test kit on an adequate anterior nasal specimen, in accordance with the manufacturer's instructions. A negative initial RAT should be repeated within one hour.
- •Presence of fever at time of screening of ≥38.0 ºC (≥100.4 ºF) taken orally, or ≥38.5 ºC (≥101.2 ºF) taken rectally. A subject self-report of a history of fever or feverishness within the 24 hours prior to screening will also qualify for enrollment in the absence of documented fever at the time of screening.
- •Presence of at least one respiratory symptom (cough, sore throat, or nasal symptoms) of at least moderate severity.
- •Presence of at least one constitutional symptom (myalgia [aches and pains], headache, feverishness, or fatigue) of at least moderate severity.
- •Onset of symptoms no more than 36 hours before presentation for screening.
- •Written informed consent.
排除标准
- •Women who are pregnant or breast-feeding.
- •Presence of clinically significant signs of acute respiratory distress
- •History of severe chronic obstructive pulmonary disease (COPD) or severe persistent asthma.
- •History of heart failure or angina requiring daily pharmacotherapy with symptoms consistent with New York Heart Association Class III or IV functional status within the past 12 months.
- •Screening ECG which suggests acute ischemia or presence of medically significant dysrhythmia.
- •History of chronic renal impairment requiring hemodialysis and/or known or suspected to have moderate or severe renal impairment (actual or estimated creatinine clearance <50 mL/min).
- •Clinical evidence of worsening of any chronic medical condition (temporally associated with the onset of symptoms of influenza) which, in the investigator's opinion, indicates that such finding(s) could represent complications of influenza.
- •Current clinical evidence, including clinical signs and/or symptoms consistent with otitis, bronchitis, sinusitis and/or pneumonia, or active bacterial infection at any body site that requires therapy with oral or systemic antibiotics.
- •Presence of immunocompromised status due to chronic illness, previous organ transplant, or use of immunosuppressive medical therapy which would include oral or systemic treatment with > 10 mg prednisone or equivalent on a daily basis within 30 days of screening.
- •Currently receiving treatment for viral hepatitis B or viral hepatitis C.
- •Presence of known HIV infection with a CD4 count <350 cell/mm
- •Current therapy with oral warfarin or other systemic anticoagulant.
- •Receipt of any doses of rimantadine, amantadine, zanamivir, or oseltamivir in the 7 days prior to screening.
- •Immunized against influenza with live attenuated virus vaccine (FluMist®) in the previous 21 days.
- •Immunized against influenza with inactivated virus vaccine within the previous 14 days.
- •Receipt of any intramuscular injection with the previous 7 days.
- •History of alcohol abuse or drug addiction within 1 year prior to admission in the study.
- •Participation in a previous study of intramuscular or intravenous peramivir or previous participation in this study.
- •Participation in a study of any investigational drug or device within the last 30 days.
研究组 & 干预措施
Peramivir 600 mg
Experimental
600 mg peramivir administered as bilateral 2-mL intramuscular injection.
干预措施: Peramivir (Drug)
Placebo
Placebo Comparator
Placebo (buffered diluent) administered as bilateral 2-mL intramuscular injection.
干预措施: Placebo (Drug)
结局指标
主要结局
Time to Alleviation of Symptoms (Kaplan-Meier Estimate)
时间窗: Information collected twice daily beginning predose on Day 1 and through Day 9, then once daily through Day 14
The primary efficacy endpoint was the time to alleviation of symptoms calculated as the number of hours from initiation of study drug until the start of the time period in which all 7 symptoms of influenza were either absent or present at a level no greater than mild for at least 21.5 (24 hours - 10%) hours. Subjects with missing diary data were excluded and those who did not experience alleviation of symptoms were censored at the last observed symptom assessment.
次要结局
- Change in Influenza Virus Shedding(Baseline and Days 3, 4, 9)
研究者
研究点 (121)
Loading locations...
相似试验
撤回
3 期
A Study to Evaluate the Efficacy and Safety of Intravenous Peramivir in Subjects With Uncomplicated Influenza.InfluenzaNCT01224795BioCryst Pharmaceuticals1
已完成
3 期
Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment NaiveChronic Hepatitis CNCT00093093Bausch Health Americas, Inc.900
已完成
2 期
Peramivir Treatment Response in Adults Hospitalized for Influenza-associated Lower Respiratory Tract InfectionsInfluenzaNCT02665351Chinese University of Hong Kong16
已完成
3 期
Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant RecipientsCytomegalovirus InfectionsNCT00411645Shire681
终止
3 期
A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Hospitalized Participants With Influenza A InfectionInfluenza ANCT03376321Janssen Research & Development, LLC334